Further Analysis of Vacc-4x Phase IIb Study Shows a Statistically Significant Reduction in Viral Load Over Placebo -- Previous Decision to Put Vacc-4x on Hold Has Been Reversed OSLO, NORWAY--(Marketwire - November 18, 2010) - After further analyses of the international, randomized, double-blind, placebo-controlled multi-center phase IIb study of Bionor Pharma's (OSLO:...

Henrik Lund MD Ph.D, Former Global VP in Clinical Development at Astra Zeneca, Named New CEO of Bionor Pharma ASA OSLO, NORWAY--(Marketwire - August 30, 2010) -  Bionor Pharma (OSLO: BIONOR) today announced that Henrik Lund MD Ph.D, will take over the position of CEO from Trond Syvertsen effective from 1...

Two Thirds of Study Volunteers Respond to First-Ever "Re-Vaccination" of Vacc-4x, Bionor Pharma's Peptide-Based Therapeutic HIV-Vaccine OSLO, NORWAY and WASHINGTON, DC--(Marketwire - August 30, 2010) -   Study Highlights: 25 volunteers from previously conducted Phase 2a trial were "re-vaccinated" with the vaccine after 7...

Researchers Present Findings Today at the XVIII International AIDS Conference, Vienna Austria VIENNA, AUSTRIA--(Marketwire - July 22, 2010) -  Researchers at Oslo University Hospital and Bionor Pharma's subsidiary, Bionor Immuno AS today presented results from a recently conducted...

UPDATE: NutriPharma ASA and Subsidiary Bionor Immuno AS Change Name to Bionor Pharma ASA; New Board Selected by Shareholders at Annual General Meeting OSLO, NORWAY--(Marketwire - May 27, 2010) -  Norwegian Nutri Pharma ASA (OSLO: NUT) and its subsidiary Bionor Immuno AS today announced that the parent Company Nutri Pharma ASA will now be known...